Can Surgery Partners, Inc. cover its short-term obligations?

Its current ratio is 1.86 — current assets exceed current liabilities.

Where does Surgery Partners, Inc.'s balance sheet data come from?

Every line is extracted from Surgery Partners, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Surgery Partners, Inc. SGRY Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$182.3M-20.5%	$239.9M-11.0%	$203.4M-8.3%	$250.1M+17.1%	$229.3M+23.8%
Accounts receivable, net	$603.4M+5.7%	$602.2M+4.0%	$579.3M+6.7%	$563.1M+7.6%	$570.6M+15.4%
Inventories	$100.5M+14.1%	$96.6M+9.3%	$92.3M+12.6%	$87.3M+7.9%	$88.1M+14.4%
Prepaid expenses and other current assets	$38.8M+6.9%	$41.1M+12.9%	$44.7M-1.1%	$45.9M+2.7%	$36.3M+14.5%
Total current assets	$1.08B+0.7%	$1.15B+2.8%	$1.1B+6.4%	$1.11B+9.2%	$1.07B+19.9%
Property and equipment, net	$1.13B-1.4%	$1.15B+88,623%	$1.16B+15.9%	$1.18B+17.3%	$1.15B+17.1%
Accumulated depreciation	$686M+16.9%	$651.2M+17.6%	$619.7M+10.9%	$588.8M+13.4%	$587M+20.9%
Total property and equipment, gross	——	——	——	——	——
Operating lease right-of-use assets	$281.5M+1.4%	$289.2M+366,075,949,267%	$275.7M-7.3%	$271.7M+1.8%	$277.7M+7.8%
Goodwill	$5.21B+1.5%	$5.19B+2.5%	$5.09B+5.7%	$5.1B+6.1%	$5.13B+16.6%
Deferred tax assets	$52.1M+33.9%	$53.4M-62.6%	$42.6M-46.2%	$37.4M-54.3%	$38.9M-55.3%
Other non-current assets	$72.8M+30.5%	$56.8M-1.2%	$40.7M-1.0%	$38.1M+5.8%	$55.8M-50.4%
Equity method investments	$225.4M+3.1%	$234M+8.6%	$229.4M+6.8%	$220.2M-3.0%	$218.6M+15.8%
Total assets	$8.04B+1.2%	$8.12B+2.9%	$7.95B+5.5%	$7.95B+6.2%	$7.95B+14.0%
Accounts payable	$168.6M+2.2%	$208.7M0.0%	$174.6M+2.2%	$174.9M+0.5%	$165M-5.2%
Accrued expenses	$77.1M+15.1%	$64.9M+7.5%	$69.9M+7.7%	$59.3M-6.0%	$67M-2.3%
Current portion of long-term debt	$100.4M-3.4%	$99.3M-2.1%	$103M+5.9%	$110M+19.0%	$103.9M+34.6%
Operating lease liabilities, current	$42.2M+6.6%	$42.7M+4.1%	$41.3M-0.2%	$39.6M+0.8%	$39.6M+4.8%
Finance Lease Liability, Current	——	——	——	——	——
Accrued interest	$41.9M+49.1%	$19.5M+45.5%	$30.5M+2.0%	$13.6M-18.6%	$28.1M+26.0%
Derivative liabilities	$10.5M-11.0%	$13.8M+43.8%	$14.4M-21.7%	$13.3M-5.7%	$11.8M-17.5%
Total current liabilities	$581.7M+2.2%	$615.5M-1.4%	$586M+1.9%	$573.3M+3.9%	$569.4M+8.8%
Long-term debt	$3.71B+4.6%	$3.7B+9.8%	$3.56B+11.7%	$3.58B+14.1%	$3.55B+23.7%
Operating lease liabilities, non-current	$271.9M-0.4%	$279.9M-4.2%	$266.3M-7.0%	$263.7M+2.4%	$272.9M+8.9%
Finance Lease Liabilities (Total)	$925.7M+6.8%	$935.5M+17.1%	$908.9M+25.6%	$901.9M+26.6%	$866.6M+23.0%
Operating Lease Liabilities (Total)	$314.1M+0.5%	$322.6M-3.2%	$307.6M-6.2%	$303.3M+2.2%	$312.5M+8.4%
Finance lease liabilities	$886.4M+6.5%	$896.5M+17.1%	$870.2M+25.4%	$865.4M+26.5%	$832.3M+22.7%
Other non-current liabilities	$41.6M+20.2%	$41.2M+36.4%	$38.1M+25.7%	$36.3M+72.0%	$34.6M-25.3%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%	$1.3M0.0%
Additional paid-in capital	$2.55B+0.9%	$2.54B+0.8%	$2.54B+1.2%	$2.54B+1.1%	$2.53B+1.2%
Retained earnings	-$851.1M-9.8%	-$815.2M-10.6%	-$800.2M-27.3%	-$777.5M-30.2%	-$775M-33.3%
Accumulated other comprehensive income (loss)	-$10.5M+11.0%	-$13.8M-388%	-$14.4M-237%	-$13.3M-136%	-$11.8M-123%
Redeemable noncontrolling interests	$383.4M-10.9%	$395.5M-9.9%	$411M-5.8%	$422.4M-4.5%	$430.5M+33.0%
Noncontrolling interests	——	——	——	——	——
Total stockholders' equity	$1.69B-3.0%	$1.71B-4.3%	$1.73B-8.8%	$1.75B-10.5%	$1.74B-11.5%
Total liabilities and stockholders' equity	$8.04B+1.2%	$8.12B+2.9%	$7.95B+5.5%	$7.95B+6.2%	$7.95B+14.0%
Other current assets	$157.5M+4.8%	$170.9M+17.1%	$182.5M+26.8%	$158.9M+5.9%	$150.3M+39.6%
Deferred Tax Assets and Other Non-Current Assets	$72.8M+30.5%	$11.2M+13.1%	$40.7M-1.0%	$38.1M+5.8%	$55.8M-50.4%
Finance lease right-of-use assets	——	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	——	——	——	——	——
Goodwill and Intangible Assets, Net	$5.25B+1.4%	$5.24B+2.4%	$5.13B+5.6%	$5.14B+5.8%	$5.17B+16.2%
Indefinite-Lived Intangible Assets	——	——	——	——	——
Indefinite-Lived Intangible Assets, Gross	——	——	——	——	——
Indefinite-Lived Research and Development Assets	——	——	——	——	——
Indefinite-Lived Trademarks	——	——	——	——	——
Net Investment in Lease	$281.5M+1.4%	$289.2M-2.2%	$275.7M-7.3%	$271.7M+1.8%	$277.7M+7.8%
Goodwill and intangible assets, net	$5.25B+1.4%	$5.24B+2.4%	$5.13B+5.6%	$5.14B+5.8%	$5.17B+16.2%
Investments	$225.4M+3.1%	$234M+8.6%	$229.4M+6.8%	$220.2M-3.0%	$218.6M+15.8%
Operating lease right-of-use assets	$281.5M+1.4%	$289.2M-2.2%	$275.7M-7.3%	$271.7M+1.8%	$277.7M+7.8%
Other non-current assets	$72.8M+30.5%	$56.8M-1.2%	$40.7M-1.0%	$38.1M+5.8%	$55.8M-50.4%
Property, plant and equipment, net	$1.13B-1.4%	$1.15B+6.0%	$1.16B+15.9%	$1.18B+17.3%	$1.15B+17.1%
Operating Lease Right-of-Use Assets in Other Assets	$281.5M+1.4%	$289.2M-2.2%	$275.7M-7.3%	$271.7M+1.8%	$277.7M+7.8%
Software and Technology Licenses, Net	$72.8M+30.5%	$56.8M-1.2%	$40.7M-1.0%	$38.1M+5.8%	$55.8M-50.4%
Accrued Manufacturing Costs	$77.1M+15.1%	$64.9M+7.5%	$69.9M+7.7%	$59.3M-6.0%	$67M-2.3%
Compensation and benefits	$77.1M+15.1%	$64.9M+7.5%	$69.9M+7.7%	$59.3M-6.0%	$67M-2.3%
Other accrued liabilities	$235.6M+0.9%	$242.6M-4.5%	$238.5M-1.5%	$229.1M+3.1%	$233.5M+14.7%
Current Portion of Long-Term Debt and Finance Lease Obligations	$100.4M-3.4%	$99.3M-2.1%	$103M+5.9%	$110M+19.0%	$103.9M+34.6%
Customer Collateral Liabilities	$46.3M+19.9%	$46.6M+46.5%	$42.8M+45.6%	$35.2M+17.3%	$38.6M+49.6%
Payables to Brokerage Clients	$46.3M+19.9%	$46.6M+46.5%	$42.8M+45.6%	$35.2M+17.3%	$38.6M+49.6%
Self-Insurance Reserve	$26.9M+36.5%	$23.9M+24.5%	$23M+27.1%	$23.8M+30.1%	$19.7M+3.1%
Debt Maturity - 2027	——	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$31.2M-2.2%	$32M-2.7%	$30.8M-9.7%	$31.7M-9.4%	$31.9M+21.8%
Deferred Tax Liabilities - Leasing Arrangements	——	——	——	——	——
Long-Term Debt and Finance Lease Obligations	$3.61B+4.8%	$3.6B+10.2%	$3.46B+11.8%	$3.47B+14.0%	$3.45B+23.4%
Accrued expenses and other liabilities	$98M-8.0%	$129.1M-9.7%	$110.6M-2.8%	$125.4M—	$106.5M—
Total debt	$5.05B+4.6%	$5.06B+9.9%	$4.88B+12.5%	$4.89B+15.5%	$4.83B+22.7%
Unrecognized Tax Benefits	——	——	——	——	——
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	130.8M+2.0%	129.3M+1.7%	129M+1.5%	128.2M+0.9%	128.2M+0.9%
Convertible Preferred Stock Authorized Shares	20.3M0.0%	20.3M0.0%	20.3M0.0%	20.3M0.0%	20.3M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Share-Based Payment Award Options Outstanding - Number	——	——	——	——	——
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	——	——	——	——	——
Aggregate Notional Principal Outstanding	$1.37B-1.0%	$1.38B-49.8%	$1.38B-49.7%	$1.38B-49.6%	$1.39B+2.1%
Derivative Notional Amount	$1.37B-1.0%	$1.38B-49.8%	$1.38B-49.7%	$1.38B-49.6%	$1.39B+2.1%
Number of Countries of Operation	3,000%—	3,000%—	——	——	——
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$300M0.0%	$300M0.0%	$300M0.0%	$300M0.0%	$300M0.0%
Common stock, shares issued (in shares)	$130.8M+2.0%	$129.32M+1.7%	$129.02M+1.5%	$128.21M+0.9%	$128.19M+0.9%
Common Stock, Shares, Outstanding	$130.8M+2.0%	$129.32M+1.7%	$129.02M+1.5%	$128.21M+0.9%	$128.19M+0.9%
Cost report liabilities	$7.2M-65.2%	$4.7M-77.9%	$13.3M-35.7%	$15.3M-28.2%	$20.7M-13.8%
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$31.2M-2.2%	$32M-2.7%	$30.8M-9.7%	$31.7M-9.4%	$31.9M+21.8%
Deferred Tax Liabilities, Gross	——	——	——	——	——
Deferred income taxes	$52.1M—	$53.4M—	$42.6M—	——	——
Software development costs	——	——	——	——	——
Capital loss carryforwards	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets, Net of Valuation Allowance	——	——	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	——	——	——	——
Right of use liability	——	——	——	——	——
Accrued vacation and incentive compensation	——	——	——	——	——
Section 163(j) interest	——	——	——	——	——
Powder Metal Matter	——	——	——	——	——
Deferred Tax Liabilities, Net	——	——	——	——	——
Deferred Tax Liabilities, Accrued Vacation And Incentive Compensation	——	——	——	——	——
Deferred Tax Liabilities, Basis Differences of Partnerships and Joint Ventures	——	——	——	——	——
Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs	——	——	——	——	——
Federal and state intangible assets	——	——	——	——	——
Deferred Tax Liabilities, Other	——	——	——	——	——
Deferred Tax Liabilities, Property, Plant and Equipment	——	——	——	——	——
Derivative Liability Notional Amount	$10.5M-11.0%	$13.8M+43.8%	$14.4M-21.7%	$13.3M-5.7%	$11.8M-17.5%
Notional	$1.37B-1.0%	$1.38B-49.8%	$1.38B-49.7%	$1.38B-49.6%	$1.39B+2.1%
Unrecognized compensation cost related to non-vested awards	——	——	——	——	——
Insurance reimbursements	$8.6M-10.4%	$8.6M-10.4%	$9.6M-5.9%	$9.6M-5.9%	$9.6M-5.9%
Current maturities of long-term debt	$39.3M+14.6%	$39M+17.8%	$38.7M+31.2%	$36.5M+28.1%	$34.3M+30.4%
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$725.4M+1.2%	$740.4M+12.9%	$747.5M+27.0%	$751.9M+26.5%	$716.8M+21.2%
Property, plant and equipment	——	——	——	——	——
2028	——	——	——	——	——
2030	——	——	——	——	——
2031	——	——	——	——	——
2027	——	——	——	——	——
2029	——	——	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Five	——	——	——	——	——
Trademarks	——	——	——	——	——
Lease, Liability	$1.24B+5.1%	$1.26B+11.2%	$1.22B+15.7%	$1.21B+19.4%	$1.18B+18.8%
Lease, Right-Of-Use Asset	$1.01B+1.2%	$1.03B+8.2%	$1.02B+15.5%	$1.02B+18.8%	$994.5M+17.1%
Long-Term Debt and Lease Obligation	$3.61B+4.8%	$3.6B+10.2%	$3.46B+11.8%	$3.47B+14.0%	$3.45B+23.4%
Less: current maturities	$100.4M-3.4%	$99.3M-2.1%	$103M+5.9%	$110M+19.0%	$103.9M+34.6%
2028	——	——	——	——	——
2029	——	——	——	——	——
2029	——	——	——	——	——
2030	——	——	——	——	——
Thereafter	——	——	——	——	——
2027	——	——	——	——	——
Noncontrolling interests in subsidiaries	$1.41B-0.4%	$1.42B+0.8%	$1.41B+16.2%	$1.41B+15.1%	$1.42B+32.2%
Number Of States In Which Entity Operates	$30—	$30—	——	——	——
Number of surgical facilities owned	180—	176—	——	——	——
Number of surgical facilities owned, consolidated	122—	121—	——	——	——
Number of surgical facilities owned, majority interest	89—	90—	——	——	——
Preferred Stock, Par or Stated Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Preferred Stock, Shares Authorized	$20.31M0.0%	$20.31M0.0%	$20.31M0.0%	$20.31M0.0%	$20.31M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Prepaid expenses	$38.8M+6.9%	$41.1M+12.9%	$44.7M-1.1%	$45.9M+2.7%	$36.3M+14.5%
Redeemable noncontrolling interests in subsidiaries	$383.4M-10.9%	$395.5M-9.9%	$411M-5.8%	$422.4M-4.5%	$430.5M+33.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	——	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	——	——	——	——	——
Share Repurchase Program, Authorized, Amount	——	——	——	——	——
Unrecognized tax benefits	——	——	——	——	——
Number of facilities included in VIE	9—	9—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Surgery Partners, Inc. cover its short-term obligations?: Its current ratio is 1.86 — current assets exceed current liabilities.
Where does Surgery Partners, Inc.'s balance sheet data come from?: Every line is extracted from Surgery Partners, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.